Orthogen

Orthogen AG is a pioneering German biotech firm with over 25 years of experience in molecular and autologous medicine. It has developed proprietary platform technologies that harness the body's own immune mediators to address the root causes of diseases, moving beyond symptom management. The company's applications span orthopedics, pain management, veterinary medicine, aesthetics, and several autoimmune and chronic conditions, with over 400,000 treatments administered globally. Led by its founder and CEO, Dr. Peter Wehling, Orthogen operates as a private, research-driven entity aiming to shift treatment paradigms in regenerative medicine.

Proprietary autologous platform technologies that stimulate and harvest a totality of growth factors and cytokines from the patient's own immune cells. Distinct from PRP, stem cells, or autologous plasma, it aims to target underlying disease mechanisms for long-term, causal treatment.

Orthogen competes in the broad regenerative medicine and orthobiologics space, differentiating itself from ubiquitous PRP therapies and stem cell approaches. Key competitors include other private autologous therapy developers, medical device companies in orthopedics, and larger biopharma firms exploring anti-inflammatory and disease-modifying osteoarthritis drugs.